Objective To investigate the clinical effect of furmonertinib combined with whole brain radiotherapy in the treatment of non-small cell lung cancer(NSCLC)patients with brain metastases.Method A total of 90 NSCLC pa-tients with brain metastases were divided into control group(47 cases)and study group(43 cases)according to different treatment regimens.The control group received gefitinib combined with whole brain radiotherapy,and the study group re-ceived furmonertinib combined with whole brain radiotherapy.The clinical efficacy,tumor markers[cyto-keratin 19 frag-ment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],incidence of adverse reactions and quality of life[functional assessment of cancer therapy-lung(FACT-L)]were compared between the two groups.Result The disease control rate of the study group was higher than that of the control group,and the dif-ference was statistically significant(P<0.05).After treatment,the levels of CYFRA21-1,CA19-9 and CEA in two groups were lower than those before treatment,and the levels of CYFRA21-1,CA19-9 and CEA in study group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,the scores of all dimensions of FACT-L in the two groups were higher than those before treatment,and the scores of all dimensions of FACT-L in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Fur-monertinib combined with whole brain radiotherapy is effective in the treatment of NSCLC patients with brain metasta-ses,can reduce the level of tumor markers,improve the quality of life,and has a certain safety.
NETL
NSTL
万方数据
